EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
Commenting on the capital injection Thomas Fischer, CEO of EUCODIS Bioscience, said: "Following several product launches in 2009 and the recent expansion of our lipases family to 20 enzymes we continue to build our order book. Accordingly, our revenues will finance a good part of our expenses and investments this year."
Fischer continued: "Given the wealth of business opportunities in front of us, we are extremely pleased that the cash injection will help us to broaden our product range and to ramp up our sales and marketing efforts."
EUCODIS Bioscience' shareholders Pontis Capital, Wiener Wachstumsfonds, IBG, and ARAX participated in the cash injection.
Most read news
Other news from the department manufacturing
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.